Inhibition of Opioid Transmission at the μ-Opioid Receptor Prevents Both Food Seeking and Binge-Like Eating
Open Access
- 18 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 37 (12), 2643-2652
- https://doi.org/10.1038/npp.2012.128
Abstract
Endogenous opioids, and in particular μ-opioid receptors, have been linked to hedonic and rewarding mechanisms engaged during palatable food intake. The aim of this study was to investigate the effects of GSK1521498, a novel μ-opioid receptor antagonist, on food-seeking behavior and on binge-like eating of a highly preferred chocolate diet. Food seeking was measured in rats trained to respond for chocolate under a second-order schedule of reinforcement, in which prolonged periods of food-seeking behavior were maintained by contingent presentation of a reward-associated conditioned reinforcer. After reaching a stable baseline in both procedures, animals were treated with GSK1521498 (0.1, 1, and 3 mg/kg; IP) or naltrexone (NTX, 0.1, 1, and 3 mg/kg; SC). The binge eating model was characterized by four temporally contiguous phases: 1-h chow access, 2-h food deprivation, 10-min chow access, and 10-min access to either chocolate-flavoured food or standard chow. During training the rats developed binge-like hyperphagia of palatable food and anticipatory chow hypophagia (anticipatory negative contrast). Both compounds reduced binge-like palatable food hyperphagia. However, GSK1521498 reduced the impact of high hedonic value on ingestion more specifically than NTX, abolishing anticipatory chow hypophagia. GSK1521498 also dose-dependently reduced food seeking both before and after food ingestion, whereas NTX reduced food seeking only after food ingestion. Thus, while both drugs affected the hedonic value of the preferred food, GSK1521498 also directly decreased incentive motivation for chocolate. Selective μ-opioid receptor antagonism by GSK1521498 may have utility as a treatment for reducing maladaptive, palatability-driven eating behavior by reducing the motivational properties of stimuli that elicit the binge eating commonly associated with obesity.This publication has 58 references indexed in Scilit:
- Individual effects of estradiol and progesterone on food intake and body weight in ovariectomized binge ratsPhysiology & Behavior, 2011
- Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humansMolecular Psychiatry, 2011
- Reversible suppression of food reward behavior by chronic mu-opioid receptor antagonism in the nucleus accumbensNeuroscience, 2010
- Chronic suppression of μ-opioid receptor signaling in the nucleus accumbens attenuates development of diet-induced obesity in ratsInternational Journal of Obesity, 2010
- Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injectionAlcohol, 2009
- Relation of reward from food intake and anticipated food intake to obesity: A functional magnetic resonance imaging study.Journal of Abnormal Psychology, 2008
- Ovarian hormones inhibit fat intake under binge-type conditions in ovariectomized ratsPhysiology & Behavior, 2008
- Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependenceJournal of Substance Abuse Treatment, 2008
- Reinforcing effects of stimulants in humans: Sensitivity of progressive-ratio schedules.Experimental and Clinical Psychopharmacology, 2008
- Learned contextual cue potentiates eating in ratsPhysiology & Behavior, 2007